A Systematic Review of Gene Editing Therapy for Acquired Immunodeficiency Syndrome

Authors

  • Yize Zhou

DOI:

https://doi.org/10.54097/3pkgev27

Keywords:

HIV/AIDS, ZFNs, TALENs, CRISPR/Cas9, gene editing, ethical issue.

Abstract

Acquired immunodeficiency syndrome (AIDS) is a deadly immunological disease that affects the immune system and becomes more common in recent years, which is brought on by the inflection of human immunodeficiency (HIV). The treatment of AIDS has always been a major challenge for the medical community to overcome because the existing treatment methods are not universal. At present, the scientific community is focusing on gene editing therapy, and the feasible tools are zinc finger nucleases (ZFNs), transcription activator-like nucleases (TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9). Since gene editing technology has advanced so quickly, gene editing therapy is now thought to be one of the most promising AIDS treatment. Though these systems are powerful and efficient, there are still several serious challenges that scientists should face. The clinical safety issues have always existed and been controversial, especially after He Jiankui’s case that editing AIDS-resistance human embryos coming to the light. And the legal regulations were strongly criticized due to gaps in the bottom line of scientific research. This review summarizes existing applications of gene editing in AIDS with the safety and ethical issues of clinical application, searching for the relevant solutions to the current challenges.

Downloads

Download data is not yet available.

References

HIV and AIDS. Stanford Health Care (SHC) - Stanford Medical Center. (2023).

Kalidasan, V., Ravichantar, N., Muhd Besari, A., Yunus, M. A., Mohd Yusoff, N., Mohamed, Z., & Theva Das, K. (2022). Latent HIV-1 provirus in vitro suppression using combinatorial CRISPR/cas9 strategy. Gene Reports, 29, 101686.

Xiao, Q., Guo, D., & Chen, S. (2019). Application of CRISPR/Cas9-based gene editing in HIV-1/AIDS therapy. Frontiers in cellular and infection microbiology, 9, 69.

Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., et al. (2014). Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901–910.

Perez, E., Wang, J., Miller, J. et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26, 808–816 (2008).

Lederman, M.M. et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306, 485–487 (2004).

Asmamaw, M., & Zawdie, B. (2021). Mechanism and applications of CRISPR/Cas-9-mediated genome editing. Biologics: Targets and Therapy, 353-361.

Fadel, H. J., Morrison, J. H., Saenz, D. T., Fuchs, J. R., Kvaratskhelia, M., Ekker, S. C., & Poeschla, E. M. (2014). Talen knockout of the psip1 gene in human cells: Analyses of HIV-1 replication and allosteric integrase inhibitor mechanism. Journal of Virology, 88(17), 9704–9717.

Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y. (2013). Harnessing the CRISPR/cas9 system to disrupt latent HIV-1 provirus. Scientific Reports, 3(1).

Xu, L., Yang, H., Gao, Y., Chen, Z., Xie, L., Liu, Y., Liu, Y., Wang, X., Li, H., Lai, W., He, Y., Yao, A., Ma, L., Shao, Y., Zhang, B., Wang, C., Chen, H., & Deng, H. (2017). CRISPR/Cas9-mediated CCR5 ablation in human hematopoietic stem/progenitor cells confers HIV-1 resistance in vivo. Molecular Therapy, 25(8), 1782–1789.

Luo, Z. (2019). Consideration of ethical issues arising from gene editing technology. Qianyanguancha, 68.

Shi, X. & Zhang, L. (2019). Analysis of legal liability in the experiment of "gene-edited babies". Medicine and philosophy, 40(2), 4.

Krimsky, S. (2019). Ten ways in which He Jiankui violated ethics. Nature Biotechnology, 37(1), 19-20.

Jin, Y. (2019). Legal regulation of gene editing technology: a case study of gene editing technology for AIDS immunity. Chongqing Xingzheng, 1.

Huang, P. (2019). A brief discussion on the new challenges brought by the gene-edited baby incident to the management of scientific and technological innovation. Yunnan Keji Guanli, 15(2), 4.

Downloads

Published

29-12-2023